Literature DB >> 32444373

The Roach Equation: Value of Old Clinical Tools in the Era of New Molecular Imaging.

Yun Rose Li1, Mack Roach2.   

Abstract

Entities:  

Mesh：

Year:  2020        PMID： 32444373      PMCID： PMC7456176          DOI： 10.2967/jnumed.120.246736

Source DB:  PubMed          Journal:  J Nucl Med        ISSN： 0161-5505            Impact factor:   11.082


× No keyword cloud information.
  14 in total

1.  Indications for pelvic nodal treatment in prostate cancer should change. Validation of the Roach formula in a large extended nodal dissection series.

Authors:  Firas Abdollah; Cesare Cozzarini; Nazareno Suardi; Andrea Gallina; Umberto Capitanio; Marco Bianchi; Manuela Tutolo; Andrea Salonia; Mariangela La Macchia; Nadia Di Muzio; Patrizio Rigatti; Francesco Montorsi; Alberto Briganti
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-11-16       Impact factor: 7.038

2.  External Beam Radiation Therapy (EBRT) and High-Dose-Rate (HDR) Brachytherapy for Intermediate and High-Risk Prostate Cancer: The Impact of EBRT Volume.

Authors:  Hannah Tharmalingam; Yatman Tsang; Ananya Choudhury; Roberto Alonzi; James Wylie; Imtiaz Ahmed; Ann Henry; Catherine Heath; Peter J Hoskin
Journal:  Int J Radiat Oncol Biol Phys       Date:  2019-10-11       Impact factor: 7.038

3.  Preliminary results of a 68 Ga-PSMA PET/CT prospective study in prostate cancer patients with occult recurrence: Diagnostic performance and impact on therapeutic decision-making.

Authors:  Caroline Rousseau; Maelle Le Thiec; Ludovic Ferrer; Daniela Rusu; Aurore Rauscher; Bruno Maucherat; Mathieu Frindel; Pierre Baumgartner; Vincent Fleury; Antoine Denis; Agnes Morel; Nicolas Varmenot; Emilie Debeaupuis; Loic Campion; Francoise Kraeber-Bodéré
Journal:  Prostate       Date:  2019-08-17       Impact factor: 4.104

4.  Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG/RTOG 9413): long-term results of a randomised, phase 3 trial.

Authors:  Mack Roach; Jennifer Moughan; Colleen A F Lawton; Adam P Dicker; Kenneth L Zeitzer; Elizabeth M Gore; Young Kwok; Michael J Seider; I-Chow Hsu; Alan C Hartford; Eric M Horwitz; Kosj Yamoah; Christopher U Jones; Jeff M Michalski; W Robert Lee; Thomas M Pisansky; Rachel Rabinovitch; Marvin Rotman; Rodger M Pryzant; Harold E Kim; Charles R Thomas; William U Shipley; Howard M Sandler
Journal:  Lancet Oncol       Date:  2018-10-10       Impact factor: 41.316

5.  Impact of 68Ga-PSMA-11 PET staging on clinical decision-making in patients with intermediate or high-risk prostate cancer.

Authors:  Daniela A Ferraro; Helena I Garcia Schüler; Urs J Muehlematter; Daniel Eberli; Julian Müller; Alexander Müller; Roger Gablinger; Helmut Kranzbühler; Aurelius Omlin; Philipp A Kaufmann; Thomas Hermanns; Irene A Burger
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-12-04       Impact factor: 9.236

6.  Prostate-only Versus Whole-pelvis Radiation with or Without a Brachytherapy Boost for Gleason Grade Group 5 Prostate Cancer: A Retrospective Analysis.

Authors:  Kiri A Sandler; Ryan R Cook; Jay P Ciezki; Ashley E Ross; Mark M Pomerantz; Paul L Nguyen; Talha Shaikh; Phuoc T Tran; Richard G Stock; Gregory S Merrick; David Jeffrey Demanes; Daniel E Spratt; Eyad I Abu-Isa; Trude B Wedde; Wolfgang Lilleby; Daniel J Krauss; Grace K Shaw; Ridwan Alam; Chandana A Reddy; Daniel Y Song; Eric A Klein; Andrew J Stephenson; Jeffrey J Tosoian; John V Hegde; Sun Mi Yoo; Ryan Fiano; Anthony V D'Amico; Nicholas G Nickols; William J Aronson; Ahmad Sadeghi; Stephen C Greco; Curtiland Deville; Todd McNutt; Theodore L DeWeese; Robert E Reiter; Jonathan W Said; Michael L Steinberg; Eric M Horwitz; Patrick A Kupelian; Christopher R King; Amar U Kishan
Journal:  Eur Urol       Date:  2019-04-13       Impact factor: 20.096

Review 7.  Predicting the risk of lymph node involvement using the pre-treatment prostate specific antigen and Gleason score in men with clinically localized prostate cancer.

Authors:  M Roach; C Marquez; H S Yuo; P Narayan; L Coleman; U O Nseyo; Z Navvab; P R Carroll
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-01-01       Impact factor: 7.038

8.  Prospective evaluation of 68Gallium-prostate-specific membrane antigen positron emission tomography/computed tomography for preoperative lymph node staging in prostate cancer.

Authors:  Pim J van Leeuwen; Louise Emmett; Bao Ho; Warick Delprado; Francis Ting; Quoc Nguyen; Phillip D Stricker
Journal:  BJU Int       Date:  2016-06-18       Impact factor: 5.588

9.  Lymph Node Involvement in Treatment-Naïve Prostate Cancer Patients: Correlation of PSMA PET/CT Imaging and Roach Formula in 280 Men in Radiotherapeutic Management.

Authors:  Stefan A Koerber; Gerald Stach; Clemens Kratochwil; Matthias F Haefner; Henrik Rathke; Klaus Herfarth; Klaus Kopka; Tim Holland-Letz; Peter L Choyke; Uwe Haberkorn; Juergen Debus; Frederik L Giesel
Journal:  J Nucl Med       Date:  2019-07-13       Impact factor: 11.082

10.  68Gallium-labelled PSMA-PET/CT as a diagnostic and clinical decision-making tool in Asian prostate cancer patients following prostatectomy.

Authors:  Janice S H Tan; Charles X Y Goh; Yen Sin Koh; Youquan Li; Jeffrey K L Tuan; Eu Tiong Chua; Terence W K Tan; Michael L C Wang; Lui Shiong Lee; Kae Jack Tay; Ravindran Kanesvaran; Chee Keong Toh; Aaron K T Tong; Winnie W C Lam; Melvin L K Chua
Journal:  Cancer Biol Med       Date:  2019-02       Impact factor: 4.248
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.